Abstract
Breast cancer (BC) is the most frequently diagnosed type of cancer in women. Nevertheless, cases in the male population have also increased in recent times. Nonselective delivery of anticancer drugs by conventional drug delivery systems exhibits substantial side-effects including a compromised immune system, neutropenia, and baldness. Moreover, drug bioavailability is drastically reduced due to the high first-pass effect and para-glycoprotein (P-gp) mediated efflux as the majority of drugs are substrates to CYP3A4 and P-gp pumps. Recently, with the enhanced understanding of the tumor biology, metastasis, and site-specific delivery of anticancer drugs by nanoparticulate systems like liposomes, solid lipid nanoparticles, nanostructured lipid carriers, self-emulsifying drug delivery systems, lipoproteins, lipid nanocapsules, polymeric micelles, mixed micelles, layerosomes, niosomes, carbon nanotubes, and dendrimers have exhibited reduced side effects, enhanced bioavailability for anticancer drugs, and an overall enhancement in the cancer therapeutics. Hence, this chapter will provide an in-depth understanding of the nanoparticle systems explored for BC management with their preclinical and clinical status.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Advanced Drug Delivery Systems in the Management of Cancer
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
